Non-prostanoid prostacyclin agonists for the treatment of pulmonary arterial hypertension

Abstract

Pulmonary arterial hypertension (PAH) is a rare disease with various causes. Vasoconstriction, in situ thrombosis and thickening of the smaller pulmonary artery walls leads to an increase in pulmonary artery pressure, right heart failure and eventually death. Currently, several specific therapies are available for PAH treatment, including sildenafil citrate, bosentan, epoprostenol and prostanoid derivatives. ONO-1301 is a long-acting non-prostanoid prostacyclin agonist, which is currently in development for several conditions including PAH. This is a proof-of-concept study demonstrating antiremodelling and -thrombotic activity and vasodilatory properties of ONO-1301 in moncrotaline-induced PAH rat model.

Keywords::

• experimental PAH
• non-prostanoid prostacyclin agonists
• pulmonary arterial hypertension